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Background and aims: Inflammatory bowel diseases are part of a wider conglomeration of
immune-mediated inflammatory diseases. New management approaches need to be developed
as we understand more of the epidemiology and aetiology of inflammatory bowel diseases and
medical care becomes more complex.
Methods: Selected new tools and approaches for improved management of inflammatory bowel
diseases are presented, based on published evidence and clinical experience.
Results: Setting quality of care standards that are consistent across different inflammatory
bowel disease care settings will be paramount and require collaboration between specialist and
non-specialist centres. Alongside this, the value of care will need to be evaluated in terms of
maximising outcomes over the entire care cycle for a patient. In moving towards a value-based
approach to management, it is important to determine the progression rate of the disease by
measuring cumulative bowel damage. As well as understanding the course of disease in
individual patients, it is also becoming more feasible to individualise therapy and exploit drugylates; IMID, immune-mediated inflammatory diseases; IPNIC, International Program to develop New
clonal antibody.
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1247New tools and approaches in IBDpharmacology to achieve better and more long-term responses. Finally, it is timely to consider
formal collaborations between specialists in immune-mediated inflammatory diseases to ensure
more cohesive patient care.
Conclusions: The potential for improved management of patients with inflammatory bowel
diseases continues to increase as we look to understand when and how to intervene in the
disease process and how to adopt a collaborative management approach that promotes
networking and reduces heterogeneity of care across different care settings.
© 2014 European Crohn's and Colitis Organisation. Published by Elsevier B.V. Open access under CC BY-NC-ND license.1. Introduction
Inflammatory bowel diseases (IBD) represent a chronic and
complex spectrum of diseases that are part of a wider
conglomeration of immune-mediated inflammatory diseases
(IMIDs) such as rheumatoid arthritis, psoriatic arthritis,
psoriasis, spondyloarthropathies and systemic lupus erythe-
matosus. As we understand more of the epidemiology and
aetiology of IBD and medical care becomes more complex,
new management approaches need to be developed. This
will involve setting quality standards that are consistent
across different IBD care settings, careful evaluation of the
value of IBD care, developing more sophisticated methods to
monitor disease progression, tailoring drug therapy to individ-
ual patients and synergistic collaborations with other IMID
specialists.2. Reducing discrepancies across different IBD
care settings
In an ideal scenario, patients would be able to access the same
standard of care irrespective of where they lived or went for
treatment. In reality, notable variations in an individual IBD
patient's care exist. This is influenced by a number of variables
including the patient's type of care facility, their geographical
location (within and between countries), standards of treat-
ment, philosophies of treatment, adherence to clinical guide-
lines, patient and physician preferences, access to support staff
and payer perspectives.
Several retrospective or cross-sectional studies have
illustrated country-specific and care setting-specific varia-
tions in IBD care, although it is not yet clear as to whether
such differences are detrimental to clinical outcomes.1,2 A
recent comparison of prescription rates among elderly
patients with IBD in the USA, UK, Denmark and Canada
found a high degree of variability between the four
countries.3 In Crohn's disease (CD), the USA had the highest
rate of thiopurine usage and Canada had the highest rate of
methotrexate prescriptions. Both North American countries
prescribed higher rates of oral 5-aminosalicylates (5-ASA)
and infliximab than the UK or Denmark. In patients with
ulcerative colitis (UC), oral steroid prescriptions were
highest in the USA and lowest in the UK, and oral 5-ASA
use was highest in the USA and Canada. Infliximab and
adalimumab prescriptions were significantly higher in the
USA than other countries. However, while this analysis shows
notable differences in prescription patterns across regions,
it gives us little insight into the actual impact (if any) ofthese differences in care on clinical outcomes. Most
recently, the POLARIS study has provided interesting insight
into variance in treatment patterns and quality of care from
the perspective of patients with CD and their healthcare
providers (HCPs), with preliminary results showing greater
use of immunomodulators and biologics in IBD centres
compared with non-IBD centres.4 Of course, it is likely that
patients attending IBD centres have more severe disease
and, therefore, are more likely to be prescribed aggressive
therapy than those attending non-specialist centres. Further
analysis of this study should evaluate whether care setting
(both in terms of country and in terms of specialist vs.
non-specialist centre) has an independent effect on clinical
outcome in CD patients.
Efforts to set standards in quality of care are underway in
various geographical and specialist society jurisdictions.
Clinical quality indicators to guide, monitor and improve the
quality of IBD care have been developed by several groups
over the past few years and provide an important step
towards delivery of consistent, evidence-based care that
meets a specific minimum standard.5–7 In addition to this, we
require well-designed prospective studies to understand this
variation in care in terms of outcome. The cluster-randomised
REACT study (NCT01030809), which is evaluating a treatment
algorithm compared with usual care for the management of
CD, should provide valuable insight into the impact of tailoring
therapy to meet precise treatment goals on the likelihood of
remaining in remission at 24 months' follow-up. This is the first
cluster-randomised study to be performed across different IBD
care settings.
Given the wide variation in IBD care, it is proposed that a
network model is used within an IBD centre to reduce
heterogeneity in care, with an example shown in Fig. 1. This
type of model would allow non-IBD centres to reach out to
IBD centres that, in turn, could access important specialist
services, allowing care to be harmonised across different
settings.3. Moving towards value-based healthcare
for IBD
IBD is an expensive chronic disease, with substantial direct
and indirect costs.8–11 These are further increased in
patients with fistulising disease,12 patients with more severe
disease13 or patients who are non-adherent to therapy.14
While improving quality of care in IBD is a laudable goal, this
may also result in increases in cost that need to be balanced
against longer term improvements in patient outcomes.
Figure 1 A proposed model of networking within an IBD centre, allowing harmonisation of IBD care. IBD care takes place in a variety
of different settings, including specialist-IBD centres, non-specialist centres, community-based gastroenterology practices, surgical
centres (including those that specialise in colorectal surgery) and general practitioner clinics. In a large IBD centre, essential
components include a triage centre, an ambulatory outpatient centre, a hospital or inpatient service and surgical service including an
operating room. Facilities for clinical research, animal research, human biomaterial research and tissue banking should be available.
Support services such as radiology, endoscopy and a clinical trials centre are also included in the model. In the network, other
affiliated centres (such as non-specialist or community centres, surgical centres and primary care centres) may access all services
through the specialist IBD centre.
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from charging a fee for services to receiving payment for
quality care. In other words, we need to improve the actual
health outcomes for each dollar spent, rather than simply
providing less costly services.15,16 Value-based healthcare
involves maximising outcomes over the entire care cycle for
a patient, as opposed to minimising the cost of each specific
intervention.15,16 This is particularly relevant in a chronic
disease such as IBD. Value can be expressed as a value
quotient, with outcomes as the numerator and total costs as
the denominator. Of course, for the value quotient to be
calculated, outcomes must firstly be measured, reported
and compared. These should include health benefit, quality
of life and productivity.
Prioritising and measuring value improvement in IBD has
the potential to empower and deliver good outcomes for our
patients with this disease,with the further ability to allow cost
efficacy to be re-examined in the context of a full cycle of
care. In an anecdotal example of value-based healthcare, the
University of California at Los Angeles Center for Inflammatory
Bowel Diseases has developed a novel approach to measuring
and improving value for patients with IBD (http://gastro.ucla.
edu/body.cfm?id=138). In this model, patients participate
in their own care through enrolling in online programmes
focusing on disease education, work ability, mental health and
disease research. Clinicians adhere to a tight disease control
infrastructure, which includes proactive clinical management
of IBD based on the most up-to-date IBD practice guidelines.
Patients use personal communications devices to submit
information on their current disease activity, quality of life,
work productivity and laboratory data to the centre, and
care is fine-tuned around these inputs. This allows the value
of care to be assessed and improved by channelling patients
and healthcare providers towards the most achievable and
cost-effective value quotients for individual patients.At present, we only have anecdotal evidence to support
the benefits of a value-based approach to IBD care. The
impact of such a programme on actual clinical outcomes
including disease recurrence, requirement for surgery,
disease progression and disability needs to be evaluated
in a robust fashion, together with complementary quality
of life and cost–benefit analyses, to determine its wider
utility.
4. Capturing bowel damage in Crohn's disease—
the Lémann score
It is becoming increasingly evident that CD has a natural
history that leads to irreversible bowel damage, with
intestinal resection required in the large majority of
patients.17 In moving towards a value-based approach to
CD management, it is important to be able to measure
cumulative damage to the bowel over time in order to
determine the progression rate of the disease.
Current scoring systems to estimate disease activity,18–21
mucosal inflammation22–24 or histological activity25 assess
the severity of disease at a specific time point without
reference to the history of the disease. Conversely, the
International Program to develop New Indexes in Crohn's
disease (IPNIC) has developed the Crohn's Disease Digestive
Damage Score (Lémann score), which is a new instrument
that measures cumulative structural bowel progression at a
specific point in an individual's disease history (based on
medical history, endoscopy and other imaging methods) and
can be used to assess the impact of treatment strategies on
the progression of digestive damage.26,27 This is the first
such score to be developed in IBD. The tool assessment
methods are damage driven — taking damage location,
severity, extent and progression of disease into account. To
Figure 2 Assessment of digestive damage using the Lémann Score: segmentation of the digestive tract. To calculate the score, the
digestive tract is divided into four organs (upper digestive tract, small bowel, colon and rectum, and anus), then each organ is divided
into segments, which are individually scored for damage on an ordinal scale ranging from 0 (normal) to 3 (maximal).26
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four organs (upper digestive tract, small bowel, colon and
rectum, and anus), then each organ is divided into segments
(3, 20, 6 and 1 segment[s], respectively) (Fig. 2). For each
segment, information about previous surgery and presence
of stricturing and/or penetrating lesions ranked per grade of
severity is recorded (Table 1). A segmental score ranging
from 0 (no lesion) to 10 (complete resection of the segment)
is given, taking into account the presence and severity of
lesions. An organ score is automatically calculated as the
sum of the segmental scores provided by the investigators
plus the scores attributed to resected segments in case
of previous resection weighted by the relative weight of
each segment within the organ. Finally, a global score is
calculated, taking into account the four organ damage
scores. This tool should provide a highly useful measurement
of the severity of bowel damage and may be used to measure
cumulative bowel damage over time. Future studies will
examine the effect of early therapeutic intervention on
damage protection in patients with CD.Table 1 Example of the scoring system used when calculating the
to the lesions or history of surgery or any other interventional
according to this ordinal scale.
Table adapted and reproduced from Pariente et al.26 with permiss
Grade Stricturing lesions Pene
0 Normal Norm
1 Wall thickening b3 mm and/or segmental
enhancement without prestenotic dilatation




3 Stricture with restenotic dilatation AbscIt is currently unclear as to whether chronic UC also has a
tendency to progress to irreversible bowel damage, although
there is some evidence that ongoing inflammation may have
a detrimental effect on the physiology of the colon, driving
proximal extension of disease and structural and functional
damage below the level of the gastrointestinal mucosa.28
The evolution of UC needs to be further characterised to
determine the respective roles of conventional therapy,
early and aggressive therapy, and surgery in preventing
complications associated with disease progression. Tools to
capture cumulative bowel damage in UC may be useful in
this process.
5. Individualising therapy with monoclonal
antibodies to optimise treatment
As well as understanding the course of disease in individual
patients, it is also becoming more feasible to predict and
modulate the effects of therapy in individual patients.Lémann score: severity scale for small bowel lesions according
procedures. Each segment within the small bowel is scored
ion from Lippincott Williams & Wilkins, Inc. © 2011.




smural fissure with increased
ity in perienteric fat
By-pass diversion or
stricturoplasty
ess or fistula Resection
Table 2 Factors influencing the pharmacokinetics of anti-tumour necrosis factor (TNF) monoclonal antibodies (mAbs).
Table adapted and reproduced from Ordás et al.31 with permission from Nature Publishing Group. © 2012.
Factor Impact on pharmacokinetics of anti-TNF mAbs




Reduces anti-drug antibody formation
Decreases mAb clearance resulting in increased serum mAb
levels
Disease severity High baseline serum TNF-α levels May decrease free serum mAb levels through binding,
thereby increasing clearance
Low baseline albumin levels Associated with increased mAb clearance
High baseline C-reactive protein levels Associated with increased mAb clearance
Personal characteristics High body weight Increases mAb clearance
High body mass index May increase mAb clearance
Higher production of TNF via adipose tissue
Reduces bioavailability of subcutaneously administered mAbs
Gender Males have higher mAb clearance, usually due to higher body
weight
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according to the needs of the individual patient rather than
using standardised regimens deduced from clinical trials, is a
more realistic goal than ever before.
Humanised monoclonal antibodies (mAbs) directed
against tumour necrosis factor (TNF)-α have had a tremen-
dous influence on the treatment of CD and UC.29 However,
while these mAbs are highly effective for induction and
maintenance of clinical remission, not all patients respond
and many patients lose response over time.29 Understanding
the principles governing the pharmacology of mAbs and how
to manipulate these may provide a means to improving
long-term response rates.30,31
Response to a drug is dependent on achieving and
maintaining adequate drug levels. Drug concentrations need
to be maintained above a target concentration in order to
see a response. The pharmacology of mAbs is complex and
depends on the structure of the antibody, the properties of
the target antigen and on patient characteristics (Table 2).
Anti-TNF mAbs used in CD and UC demonstrate linear
pharmacokinetic relationships between dose and serum
concentrations32; however, the trough level for any given
dose (that is, the serum concentration immediately before the
next dose of drug is administered) varies between patients.
This has clinical implications, as high trough concentrations
are associated with substantial clinical improvement,33 while
low trough concentrations are associated with poor clinical
response33 or greater likelihood of treatment discontinua-
tion.34 However, this is further complicated by the observa-
tion that mAbs typically have a very long delay between
exposure and measurable response because the drug has a
preliminary effect that is then propagated to achieve a
clinical effect at a later point in time. Plotting drug trough
concentrations with clinical activity is relatively meaningless
because of the time lag between drug administration and
observation of a clinical response.
Low serum mAb trough concentrations are often associ-
ated with the formation of anti-drug antibodies (ADAs).34,35
These can limit drug bioavailability and shorten half-life36
through the formation of immune complexes that acceleratedrug clearance and/or impair binding. The development of
ADAs depends on actual levels of drug exposure37 and may
also be exacerbated by drug holidays, episodic dosing and
protracted low drug concentrations. Measurable trough
concentrations need to be maintained throughout the dosing
interval to minimise the chance of developing ADAs.
Manipulating the dosing regimen of anti-TNF therapies
in IBD may be useful for maintaining measurable trough
concentrations and decreasing the likelihood of developing
ADAs. Shortening the dosing interval may be more beneficial
than increasing the drug dose because it takes approximate-
ly four to five half-lives to clear drug from the body and the
half-life does not change with dose for many mAbs. Patient
factors should also be taken into account when considering
dosing modifications. Patients with greater disease severity,
as reflected in lower albumin or higher C-reactive protein
levels, may have greater drug clearance.36,38,39 Patients
with a high TNF-receptor burden (particularly when the
disease is first diagnosed) may require a higher dose initially,
and monitoring of drug concentrations in patients with
low bodyweight is important. Furthermore, when patients
are chronically noncompliant, there is a slow fall-off in
trough levels that will not come back up unless loading
(or induction) is re-initiated. While the relationship between
low trough concentrations of mAbs and poor clinical effect has
been demonstrated,33 the correlation between higher serum
mAb levels and clinical improvement is more controversial.
It may also be that patients in remission are able to reduce
their mAb dose to maintain therapeutic trough levels, with
important drug exposure and cost benefits. The Trough level
Adapted infliXImab Treatments (TAXIT) study evaluated
treat-to-target dosing based on infliximab trough levels in
patients with IBD.40,41 In this study, 263 patients underwent an
induction phase where their infliximab dose was optimised to
achieve a target trough level of 3–7 μg/mL. During this phase
of the study, dose intensification of infliximab in CD patients
(but not UC patients) with trough levels b3 μg/ml resulted in
significantly better disease control (p = 0.02), whereas dose
reduction in CD and UC patients with trough levels N7 μg/ml
resulted in lower drug exposure while maintaining disease
1251New tools and approaches in IBDcontrol. Following infliximab dose optimisation, patients were
randomised to dose adjustment based on clinical symptoms
and C-reactive protein levels (n = 123) or based on infliximab
trough levels (n = 128). No significant between-group differ-
ences were reported in the primary endpoint of both clinical
and biological remission one year after randomisation,
although more efficient use of drug and a lower incidence of
ADA formation were seen in the group that underwent dose
adjustment based on infliximab trough level.
While there may be benefits to modifying treatment
regimens to achieve target serum trough levels of anti-TNF
therapy, further concentration-controlled clinical trials
need to be undertaken in order to further understand the
applications of this approach. A randomised double-blind
study (Netherlands Trial Register NTR3943) is currently
being performed to evaluate the cost effectiveness of trough
level-based dose reduction during maintenance treatment
for CD, which will provide further interesting insight as to
the benefits of therapeutic drug monitoring on outcomes.6. Collaborating with other IMID specialists
It is increasingly apparent that inflammatory diseases are not
discrete entities confined to a particular organ; rather, we are
finding thatmultiple different manifestations of inflammatory
disease have a generic inflammatory pathophysiology. In an
analysis of the Swiss IBD cohort, it was shown that 38% of IBD
patients had extraintestinal manifestations, including arthri-
tis, aphthous stomatitis, uveitis and ankylosing spondylitis.42
Overlapping syndromes and comorbidities are clinically
underestimated, which can have a significant impact on
patient well-being and, ultimately, mortality. Furthermore,
different genetic aetiologies can induce uniform phenotypes
of IMID and, conversely, IMIDs can present with different
phenotypes in patients with similar genetic backgrounds.43,44
It is timely to consider formal collaboration between IMID
specialists to ensure more cohesive patient care. A model of
this form of collaboration has been developed by the
Comprehensive Center for Inflammatory Medicine based at
University Hospital Schleswig-Holstein in Kiel, Germany. This
academic patient-care facility allows collaboration between
gastroenterology, dermatology, ophthalmology, pulmonology,
rheumatology, hepatology, nephrology and immunology. Clin-
ical care is integrated with basic research, which involves
in-depth phenotyping and studies of genetics, epigenetics and
epidemiology. The patient is appraised by a multidisciplinary
team and discussed in case conferences. Therapeutic decision
making is highly standardised, with specific rules of engage-
ment. These include compulsory discussion of cases before
therapy with biologics; formalised case presentation with
protocols reflecting discussion results; binding joint decisions
for the future care of the patient and standardised follow-up of
all patients. This model should allow better outcomes for all
patients with IMIDs, as well as allowing concentrated evalua-
tion of the underlying molecular basis to disease.7. Summary and conclusions
The potential for improved management of patients with IBD
continues to increase as we look to understand when andhow to intervene in the disease process. This will be
influenced by more sophisticated tools for monitoring disease
progression, such as the newly-developed Lémann score, and
greater understanding of how to manipulate treatment at an
individual level. Improving the management of IBD is likely
to require a collaborative approach to promote networking
and reduce heterogeneity of care across different IBD care
settings. Such an approach will also require collaboration
between different IMID specialities.Contributorship
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